COMMUNIQUÉS West-GlobeNewswire

Beacon Behavioral Partners Expands National Footprint with First Georgia Partnership
04/08/2026
Physician-led partnership deepens access to behavioral healthcare through partnership with AR Psychiatric & Counseling Center Georgia and strengthens its growing behavioral health network across the nation PLANO, [...]
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
04/08/2026
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic [...]
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
04/08/2026
11 tissue, blood, and cerebrospinal fluid biomarkers reflecting the biological cascade of neurodegeneration and neuroinflammation in PD respond in concert to risvodetinib treatment in patients with early untreated [...]
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
04/08/2026
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga [...]
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
04/08/2026
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of [...]
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
04/08/2026
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development [...]
Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases
04/08/2026
-- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept -- NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads [...]
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
04/08/2026
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage [...]
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned [...]
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
04/08/2026
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase [...]
Tecan schedules conference call on August 11th to discuss half year 2026 financial results
04/08/2026
Männedorf, Switzerland, August 4, 2026 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2026 on Tuesday, August 11th, 2026, at 09:00 [...]
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
04/08/2026
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategy JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026
NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277, [...]
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
04/08/2026
-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product [...]
Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases
04/08/2026
-- First-in-human trial of LBL-051 is enrolling patients with refractory autoimmune diseases to rapidly generate broad proof of concept -- Cambridge, Mass., August 4, 2026 - Oblenio Bio (“Oblenio” or “the Company”) [...]
Remix Therapeutics to Present at 46th Annual Canaccord Genuity Growth Conference
04/08/2026
WATERTOWN, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying [...]
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
04/08/2026
Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures [...]
NeurAxis Expands Payer Coverage with New Policies
04/08/2026
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]

Pages